UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• UBS Asset Management increased its stake in Edwards Lifesciences by 4.1%, owning a total of 6,783,568 shares valued at approximately $491.67 million.
• Multiple large investors are actively trading Edwards Lifesciences, with institutional investors and hedge funds owning 79.46% of the company's stock.
• Edwards Lifesciences recently received positive updates from analysts, with several firms raising their price target for the stock, reflecting a strong consensus rating of "Moderate Buy" and an average price target of around $86.45.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 4.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,783,568 shares of the medical research company's stock after purchasing an additional 264,311 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 1.16% of Edwards Lifesciences worth $491,673,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. Nuveen LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at about $330,881,000. Jennison Associates LLC grew its stake in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $92,631,000. Orbimed Advisors LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $84,787,000. Finally, Woodline Partners LP grew its stake in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company's stock worth $59,822,000 after purchasing an additional 814,917 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.7%

Shares of EW stock traded down $0.51 during trading hours on Friday, reaching $77.50. The company had a trading volume of 6,301,589 shares, compared to its average volume of 3,595,766. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a fifty day simple moving average of $78.92 and a 200-day simple moving average of $75.42. The company has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of several recent analyst reports. Royal Bank Of Canada raised their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $86.26.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,014 shares of company stock valued at $1,698,844 over the last ninety days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.